Clinical Trial Update: Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) [Phase 3]

View source ↗

Summary

Phase 3 GEMSTONE study of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemoradiotherapy for nasopharyngeal carcinoma is currently active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING